Join Growin Stock Community!

Drugs made in america acquisition corp. unitsDMAAU.US Overview

US StockIndustrials
(No presentation for DMAAU)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

DMAAU AI Insights

DMAAU Overall Performance

DMAAU AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DMAAU Recent Performance

-

Drugs made in america acquisition corp. units

-1.72%

Avg of Sector

-2.16%

S&P500

DMAAU PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

DMAAU Key Information

DMAAU Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

DMAAU Profile

Drugs Made In America Acquisition Corp. is a blank check company. It is an exempt company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company was founded on May 23, 2024 and is headquartered in Fort Lauderdale, FL.

Price of DMAAU

DMAAU FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DMAAU Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is DMAAU's latest earnings report released?

    The most recent financial report for Drugs made in america acquisition corp. units (DMAAU) covers the period of 2024Q4 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DMAAU's short-term business performance and financial health. For the latest updates on DMAAU's earnings releases, visit this page regularly.

  • How much cash does DMAAU have?

    At the end of the period, Drugs made in america acquisition corp. units (DMAAU) held Total Cash and Cash Equivalents of 822, accounting for 0 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.